mojoey
Senior Member
- Messages
- 1,213
(This is reposted from stem cell thread, thought it might be more relevant in XMRV treatment and testing section)
This is just my very barbaric hunch, but I think it's overly optimistic to think that we who have come down with ME/CFS could become like those whose immune systems are keeping XMRV at bay using therapies that do not specifically target XMRV. Just from my own observations, a full-blown remission from ME/CFS is one in a million, so I believe that once the damage is done, very few terrain-reestablishing remedies will be able to put XMRV into the state in which it once existed when we lived normal lives. In short, I'm guessing that it will be a one-way road from XMRV-pos healthy life to XMRV-pos neuro-immune disorder, without the intervention of aggressive anitretoviral activity. Many HIV-pos patients never get AIDS (e.g. Magic Johnson), but I've never heard of an AIDS patient spontaneously remitting from AIDS without ARVs. Of course, we have a different type of virus but the one-way pattern seems consistent.
One reason I say this is because I've been doing just that very type of Bechamp-based therapy using Sanum for the last 8 months and I have not improved like other patients that have tested XMRV-negative and are undergoing the same therapy. Our trajectories have looked clearly different--they have improved from this therapy and I have clearly declined in the last 8 months. Perhaps reestablishing optimal terrain will work for retroviruses but it definitely seems to take more time than those whom do not have a predominant retrovirus. Besides outward discrepancies, these other patients have shown improvement on lab results, whereas I still show the basement NK cell function and neutropenia that has bled my lab reports for the last 4 years.
After talking with Peterson, we both agree that some form of immune modulation + anti-XMRV strategy will be necessary for XMRV-pos patients. The thing with ampligen is it kills XMRV in the test tube, so that may be why it has had the track record in CFS patients that it has compared with other drugs that are purely immunomodulatory in nature, and also why many patients like Mary Schweitzer and Andrea Whittemore (as Cort reported, "who had became dangerously ill after having to go off Ampligen" - http://aboutmecfs.org/Rsrch/XMRVBuzz.aspx) relapse upon stopping the drug.
Cort recently reported:
Peterson also agrees with me that XMRV may very well be a distinguishing factor in success with stem cell therapy.
This is just my very barbaric hunch, but I think it's overly optimistic to think that we who have come down with ME/CFS could become like those whose immune systems are keeping XMRV at bay using therapies that do not specifically target XMRV. Just from my own observations, a full-blown remission from ME/CFS is one in a million, so I believe that once the damage is done, very few terrain-reestablishing remedies will be able to put XMRV into the state in which it once existed when we lived normal lives. In short, I'm guessing that it will be a one-way road from XMRV-pos healthy life to XMRV-pos neuro-immune disorder, without the intervention of aggressive anitretoviral activity. Many HIV-pos patients never get AIDS (e.g. Magic Johnson), but I've never heard of an AIDS patient spontaneously remitting from AIDS without ARVs. Of course, we have a different type of virus but the one-way pattern seems consistent.
One reason I say this is because I've been doing just that very type of Bechamp-based therapy using Sanum for the last 8 months and I have not improved like other patients that have tested XMRV-negative and are undergoing the same therapy. Our trajectories have looked clearly different--they have improved from this therapy and I have clearly declined in the last 8 months. Perhaps reestablishing optimal terrain will work for retroviruses but it definitely seems to take more time than those whom do not have a predominant retrovirus. Besides outward discrepancies, these other patients have shown improvement on lab results, whereas I still show the basement NK cell function and neutropenia that has bled my lab reports for the last 4 years.
After talking with Peterson, we both agree that some form of immune modulation + anti-XMRV strategy will be necessary for XMRV-pos patients. The thing with ampligen is it kills XMRV in the test tube, so that may be why it has had the track record in CFS patients that it has compared with other drugs that are purely immunomodulatory in nature, and also why many patients like Mary Schweitzer and Andrea Whittemore (as Cort reported, "who had became dangerously ill after having to go off Ampligen" - http://aboutmecfs.org/Rsrch/XMRVBuzz.aspx) relapse upon stopping the drug.
Cort recently reported:
Peterson also agrees with me that XMRV may very well be a distinguishing factor in success with stem cell therapy.
